Repeated administration of long-acting analogues of gonadotrophin-releasing hormone down-regulates the pituitary gonadotrophins and gonadal hormones. The activity of these compounds in premenopausal women with breast cancer has been previously noted. In an attempt to cause a highly selective medical hypophysectomy 18 consecutive postmenopausal women with symptomatic advanced breast cancer were treated with intranasal buserelin in divided dosages of either 600 or 1000 μg daily. The pituitary gonadotrophins were suppressed in all patients, without objective evidence of response. This is in contrast with an earlier finding that the long-acting analogues of gonadotrophin-releasing hormone were effective in postmenopausal patients with breast cancer.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bates T, Rubens RD, Bulbrook RD et al (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782
Beatson GT (1896a) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107
Beatson GT (1896b) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet II:162–165
Fattah DI, Chard T (1981) Method for measuring sex hormone binding globulin. Clin Chem 27:1277–1279
Harvey HA, Lipton A, Santen RJ et al. (1981) Phase II study of a gonadotropin releasing hormone analogue in postmenopausal advanced breast cancer. Proc Am Soc Clin Oncol C436
Klijn JGM, De Jong FH (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1:1213–1216
La Rossa JT, Strong MS, Melby JC (1978) Endocrinologically incomplete transphenoidal hypophysectomies with relief of bone pain in breast cancer. N Engl J Med 298:1332–1335
Manni A, Pearson OH, Brodkey J, Marshall JS (1979) Transphenoidal hypophysectomy in breast cancer. Cancer, 44: 2330–2337
McMillin JM, Seal US, Theologides A (1977) Prolactin dynamics following transphenoidal hypophysectomy for metastatic carcinoma of the breast. Cancer 39:2254–2257
Nillius S-J, Bergquist C, Wide L (1978) Inhibition of ovulation, in women by chronic treatment with a stimulatory LRH analogue — a new approach to birth control? Contraception 17:537–545
Schinzinger (1889) Über Carcinoma Mammae (abst) Zbl Chir 16:55
Wang DY, Bulbrook RD, Rubens RD et al. (1976) Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer 12:775–782
About this article
Cite this article
Waxman, J.H., Harland, S.J., Coombes, R.C. et al. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother. Pharmacol. 15, 171–173 (1985). https://doi.org/10.1007/BF00257531
- Breast Cancer
- Cancer Research
- Postmenopausal Woman
- Premenopausal Woman
- Advanced Breast